Q-omics provides the consensus-scored SP5 profile across patient tissues and cancer cell-line models. SP5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SP5 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SP5 RNA expression shows 15,563 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where SP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SP5 survival associations across molecular data types. SP5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SP5 RNA expression–survival associations across cancer types. High SP5 expression shows unfavorable associations in KIRC, ACC, LGG and CESC, but favorable associations in BRCA and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SP5 RNA expression.
This table summarizes SP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SP5 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, LUAD, READ and UCEC. The COAD box plot shows higher SP5 RNA expression in tumor versus normal tissue (log2 FC = +3.634, t-test p < 0.001).
This table shows molecular features associated with SP5 in patient tissues and cancer cell lines. In patient samples, SP5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
